~~<i id='348A64E6CC'><strike id='348A64E6CC'><tt id='348A64E6CC'><pre id='348A64E6CC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：fashion 2025-08-12 08:28:23 - browse：869

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Ionis has late

focus

knowledge

hotspot

leisure time

MetastaticmelanomacellsJulioC.Valencia,/NCICenterforCancerResearchNearlyfourdecadesafteritsfirstconc

WSS

How one patient went off dialysis — and others can too

Ukraine seeks to reclaim its role as a hub for clinical trials

Medicare drug price negotiation program allowed for now

How the Dana

Inequities make cancer less preventable for women: report

Weight loss drugs aren’t covered by Obamacare. That may change

explore

explore

focus

Duchenne breakthrough therapy leaves behind pioneering families

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Measles policy set amid Florida outbreak alarms vaccine proponents

Anesthesiologist group: stop taking Ozempic before surgery

Data show record exodus of life scientists from academia

Hollywood unions extend contract negotiations for actors

Cigna to pay $172 million to settle Medicare Advantage fraud probe

As demand for Covid shots wanes, Moderna seeks its next success

Medicare Advantage enrollment hits roughly 33.4 million

focus

Address the ethical violations that led to 'Three Identical Strangers'

A new drug could help frostbite victims avoid its ravages

Covid vaccines: Private market messier than government rollout

Hospitals are piloting generative AI tools as regulators play catch

WATCH: Why do our ears pop?

Ionis has late

focus

knowledge

hotspot

leisure time